MAM
ZNTL icon

Meeder Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Meeder Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,047
Closed -$137K – 2393
2021
Q3 		$137K Buy
2,047
+1,929
+1,635% +$111K 0.01% 820
2021
Q2 		$6K Buy
+118
New +$6.32K ﹤0.01% 1913

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Meeder Asset Management's ZNTL Position: Q4 2021 in Review

Meeder Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2021, closing a stake of 2,047 shares — an estimated $137K sold.

Meeder Asset Management first reported a position in ZNTL in Q2 2021 and held it in 2 quarters. The position peaked at $137K in Q3 2021. 139 funds tracked by Wall St. Rank hold ZNTL as of Q4 2021.

  • Meeder Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 2,047 Zentalis Pharmaceuticals shares in Q4 2021, an estimated $137K.
  • Meeder Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Meeder Asset Management's Zentalis Pharmaceuticals position peaked at $137K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.